As filed with the Securities and Exchange Commission
on September 11, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM F-3
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
Kamada Ltd.
(Exact name of registrant as specified in its charter)
Not Applicable
(Translation of registrant’s name into English)
Israel |
|
Not Applicable |
(State or other jurisdiction of |
|
(I.R.S. Employer Identification No.) |
incorporation or organization) |
|
|
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel +972 8 9406472
(Address and Telephone Number of Registrant’s Principal
Executive Offices)
Puglisi & Associates
850 Library Avenue, Suite 204
P.O. Box 885, Newark, Delaware 19715
(302) 738-6680
(Name, Address, and Telephone Number of Agent for
Service)
Copies to:
Jaclyn Liu, Esq.
Morrison & Foerster LLP
425 Market Street
San Francisco, CA 94105
(415) 268-7000 |
Sharon Rosen
FISCHER (FBC & Co.)
146 Menachem Begin Street
Tel Aviv 6492103, Israel
+972 3 6944111 |
Approximate date of commencement of proposed
sale to the public: From time to time after the effective date of this Registration Statement.
If only securities being registered on this Form
are being offered pursuant to dividend or interest reinvestment plans, please check the following box.☐
If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
☒
If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant
to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective amendment to
a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
☐ Emerging growth company.
If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities
Act. ☐
† The term “new
or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.
The registrant hereby amends this registration statement on such
date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states
that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until this
registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section
8(a), may determine.
The information in this prospectus is not complete and may be changed.
We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This
prospectus is not an offer to sell securities and it is not soliciting an offer to buy securities in any state where the offer or sale
is not permitted.
Subject to Completion, Dated September 11, 2023
Prospectus
$50,000,000
Ordinary Shares Offered by the Company
We may offer and sell from time to time in one
or more offerings up to a total amount of $50,000,000 of our ordinary shares. Each time we sell ordinary shares pursuant to this prospectus,
we will provide in a supplement to this prospectus the price and any other material terms of any such offering. We may also authorize
one or more free writing prospectuses to be provided to you in connection with each offering. Any prospectus supplement and related free
writing prospectuses may also add, update or change information contained in the prospectus. You should read this prospectus, any applicable
prospectus supplement and related free writing prospectuses, as well as the documents incorporated by reference or deemed incorporated
by reference into this prospectus, carefully before you invest in our ordinary shares.
Our ordinary shares are traded on the Nasdaq Global
Select Market and the Tel Aviv Stock Exchange under the symbol “KMDA.”
Investing in our ordinary shares involves a
high degree of risk. Risks associated with an investment in our ordinary shares will be described in any applicable prospectus supplement
and are and will be described in certain of our filings with the Securities and Exchange Commission, as described in “Risk Factors”
on page 4.
The ordinary shares may be sold directly by us
to investors, through agents designated from time to time or to or through underwriters or dealers, or through a combination of such methods,
on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan
of Distribution” in this prospectus. If any agents or underwriters are involved in the sale of our ordinary shares with respect
to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts
and over-allotment options will be set forth in a prospectus supplement. The price to the public of our ordinary shares and the net proceeds
that we expect to receive from such sale will also be set forth in a prospectus supplement.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed on completeness or the adequacy or accuracy
of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is .
TABLE
OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of
a registration statement on Form F-3 that we filed with the Securities and Exchange Commission, or the SEC, utilizing a “shelf”
registration process. Under this shelf registration process, we may offer from time to time up to an aggregate of $50,000,000 of our ordinary
shares in one or more offerings. We sometimes refer to our ordinary shares as the “securities” throughout this prospectus.
Each time we sell ordinary
shares, we will provide you with a prospectus supplement that will describe the specific amounts, prices and terms of such offering. We
may also authorize one or more free writing prospectuses to be provided to you in connection with such offering. The prospectus supplement
and any related free writing prospectuses may also add, update or change information contained in this prospectus. You should read carefully
both this prospectus, the applicable prospectus supplement and any related free writing prospectus together with additional information
described below under “Where You Can Find More Information and Incorporation by Reference” before buying the ordinary shares
being offered.
This prospectus does not contain
all of the information provided in the registration statement that we filed with the SEC. For further information about us or our ordinary
shares, you should refer to that registration statement, which you can obtain from the SEC as described below under “Where You Can
Find More Information and Incorporation by Reference.”
You should rely only on the
information contained or incorporated by reference in this prospectus, a prospectus supplement and related free writing prospectuses.
We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. This prospectus is not an offer to sell these securities and it is not soliciting an offer to
buy these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained
in this prospectus and the accompanying prospectus supplement or related free writing prospectuses is accurate on any date subsequent
to the date set forth on the front of the document or that any information that we have incorporated by reference is correct on any date
subsequent to the date of the document incorporated by reference. Our business, financial condition, results of operations and prospects
may have changed since those dates.
PROSPECTUS SUMMARY
This summary highlights
information contained in the documents incorporated herein by reference. Before making an investment decision, you should read the entire
prospectus, and our other filings with the SEC, including those filings incorporated herein by reference, carefully, including the sections
entitled “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” Unless the context indicates
otherwise, references in this prospectus to “NIS” are to the legal currency of Israel, “U.S. dollars,” “$”
or “dollars” are to United States dollars, and the terms “we,” “us,” “our company,” “our,”
and “Kamada” refer to Kamada Ltd., along with its consolidated subsidiaries.
Overview
We
are a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions
and a leader in the specialty plasma-derived field focused on diseases of limited treatment alternatives. We are also advancing an innovative
development pipeline targeting areas of significant unmet medical need. Our strategy is focused on driving profitable growth from our
significant commercial catalysts as well as our manufacturing and development expertise in the plasma-derived and biopharmaceutical markets.
We
operate in two segments: (i) the Proprietary Products segment, which includes our six U.S. Food
and Drug Administration (“FDA”)-approved plasma-derived biopharmaceutical products - CYTOGAM®,
KEDRAB®, WINRHO SDF®,
VARIZIG®, HEPGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)®, and two types of equine-based anti-snake venom
products; all of which we market internationally in more than 30 countries. We manufacture our proprietary products at our current
Good Manufacturing Practice compliant FDA-approved production facility located in Beit Kama, Israel, using our proprietary platform
technology and know-how for the extraction and purification of proteins and hyperimmune immunoglobulins (“IgGs”) from human
plasma, as well as at third party contract manufacturing facilities; and (ii) the Distribution segment, in which we leverage our expertise
and presence in the Israeli market by distributing, for use in Israel, more than 25 pharmaceutical products supplied by international
manufacturers and have recently added eleven biosimilar products to our portfolio, which, subject to European
Medicines Agency (“EMA”) and the Israeli Ministry of Health (“IMOH”)
approvals, are expected to be launched in Israel through 2028.
As
part of our Proprietary Products segment, we sell CYTOGAM, a Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV), indicated
for prophylaxis of CMV disease associated with solid organ transplantation in the United States and Canada. Total revenues from sales
of CYTOGAM for the year ended December 31, 2022, the first full year during which we sold the product, was $22.6 million.
We
market KEDRAB, a human rabies immune globulin (HRIG), in the United States through a strategic distribution and supply agreement with
Kedrion Biopharma Inc. (“Kedrion”). Our 2022 revenues from sales of KEDRAB to Kedrion totaled $16.2 million as compared to
$11.9 million and $18.3 million during 2021 and 2020, respectively. Sales of KEDRAB by Kedrion in the United States during the years 2022,
2021 and 2020 totaled $36.2 million, $24.7 million, and $23.7 million, respectively. Based on the information provided by Kedrion, these
sales represent approximately 32%, 27% and 23% share of the relevant U.S. market in each of these years, respectively. KEDRAB in-market
sales by Kedrion during 2022 grew in comparison to the pre-COVID-19 pandemic sales and we anticipate this trend to continue during 2023
and beyond.
We
believe that sales of CYTGOM and KEDRAB in the U.S. market, which generated more than 50% of gross profitability in the year ended December
31, 2022, will continue to increase in the coming years and will be a major growth catalyst for the foreseeable future.
We
sell WINRHO SDF, VARIZIG and HEPGAM B, in the United States, Canada and several other international markets, mainly in the Middle East
and North Africa (“MENA”) regions. Total revenues from sales of these products for the year ended December 31, 2022, the first
full year during which we sold these products, was $29.5 million.
For
the year ended December 31, 2022, we generated combined revenues of $52.1 million through sales of CYTOGAM, WINRHO SDF, VARIZIG and HEPGAM
B, the portfolio of four FDA-approved products that we acquired in November 2021. The 2022 revenues from this portfolio represent a 24%
year over year increase compared to the $41.9 million of total revenues generated by this portfolio during the year ended December 31,
2021.
We
market GLASSIA in the United States through a strategic partnership with Takeda Pharmaceuticals Company Limited (“Takeda”).
During 2021, Takeda completed the technology transfer of GLASSIA manufacturing to its facility in Belgium and received the required FDA
approval and initiated its own production of GLASSIA for the U.S. market. In addition, during 2021, Takeda obtained a marketing authorization
approval for GLASSIA from Health Canada. During the first quarter of 2022, Takeda began to pay us royalties on sales of GLASSIA manufactured
by Takeda, at a rate of 12% on net sales through August 2025 and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually
for each of the years from 2022 to 2040. In 2022, we received a total of $14.2 million from Takeda, of which $12.2 of sales-based royalty
income (for the period between March and December of 2022) and a $2.0 million one-time payment on account of the transfer, to Takeda,
of the GLASSIA U.S. Biologics License Application. Based on current GLASSIA sales in the U.S. and forecasted future growth, we expect
to receive royalties from Takeda in the range of $10 million to $20 million per year for 2023 to 2040 on GLASSIA sales. Historically,
we generated revenues on sales of GLASSIA, manufactured by us, to Takeda for further distribution in the United States. Our revenues from
sales of GLASSIA to Takeda totaled $26.2 million and $64.9 million during 2021 and 2020, respectively. During 2021, we also recognized
revenues of $5.0 million on account of a sales milestone associated with GLASSIA sales by Takeda.
We
also market GLASSIA in other counties through local distributors. Total revenues derived from sales of GLASSIA in all other countries
during 2022 was $5.9 million, as compared to $7.6 million and $5.5 million during 2021 and 2020, respectively. These ex-U.S. market sales
of GLASSIA generated approximately 40% gross margin in the year ended December 31, 2022.
Our
2022 revenues from the sales of the remaining Proprietary products, including KAMRAB (a human rabies immune globulin (HRIG) sold by us
outside the U.S. market) and KAMRHO (D) IM (for prophylaxis of hemolytic disease of newborns), as well as our anti-snake venoms, totaled
$13.9 million, as compared to $18.4 million and $11.2 million during 2021 and 2020, respectively.
We
own an FDA licensed plasma collection center that we acquired in March 2021 from the privately held Blood and Plasma Research, Inc (“B&PR”)
based in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D).
For the year ended December 31, 2022, we generated $0.4 million in revenues from this plasma collection center, which were included in
our Proprietary Products revenues. We are in the process of significantly expanding our hyper-immune plasma collection capacity in this
center. We obtained FDA approval for the collection of hyper-immune plasma to be used in the manufacture of KEDRAB, which is plasma that
contains high levels of antibodies from donors who have been previously vaccinated by an active rabies vaccine and plan to start collections
of such plasma during 2023. We also intend to leverage our FDA license to establish additional plasma collection centers in the United
States, with the intention of collecting normal source plasma to be sold for manufacturing by third parties, as well as hyper-immune specialty
plasma required for manufacturing of our proprietary products. We believe that the expansion of our plasma collection capabilities will
allow us to better support our plasma needs as well as generate additional revenues through sales of collected normal source plasma. To
that end, during March 2023, we entered into a lease for a new plasma collection center in Uvalde, Houston, Texas, and the construction
activities have been initiated. We expect that operations at the new center shall commence following the completion of its construction
and obtaining the required regulatory approvals.
Our
Distribution segment is comprised of sales in Israel of pharmaceutical products manufactured by third parties. Sales generated by our
Distribution segment during 2022 totaled $26.7 million, as compared to $28.1 million and $32.3 million during 2021 and 2020, respectively.
The majority of the revenues generated in our Distribution segment are from plasma-derived products manufactured by European companies,
and its sales represented approximately 75%, 84% and 89% of our Distribution segment revenues for the years ended December 31, 2022, 2021
and 2020, respectively. Over the past several years we continued to extend our Distribution segment products portfolio to non-plasma derived
products, including recently entering into an agreement with Alvotech and two additional companies for the distribution in Israel of eleven
different biosimilar products which, subject to EMA and subsequently IMOH approvals, are expected to be launched in Israel through 2028.
We believe that sales generated by the launch of the biosimilar products portfolio will become a major growth catalyst. We currently estimate
the potential aggregate peak revenues, achievable within several years of launch, generated by the distribution of all eleven biosimilar
products to be approximately $40 million annually.
In
addition to our commercial operation, we invest in research and development of new product candidates. Our leading investigational product
is Inhaled Alpha-1 antitrypsin (“AAT”) for Alpha-1 Deficiency (AATD), for which
we are continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. We
also have three new early-stage development programs of plasma derived product candidates that we initiated during 2022. These programs
include: (i) a human plasma-based eye drop for potential treatment of several conditions; (ii) an automated portable small scale system
for extraction and purification of hyperimmune IgG from convalescent plasma to be used in the hospital or blood bank setting, as an immediate
response to a variety of unmet medical needs, including pandemic outbreaks, as well as possible treatment of currently neglected or untreated
viral diseases; and (iii) a hyperimmune anti-tuberculosis IgG as a potential complementary treatment to existing standards of care, which
is developed in collaboration with the Clinical Microbiology and Immunology department of the Medicine-Sackler Faculty of Tel Aviv University
and is partially funded by the Israel Innovation Authority.
We
plan to advance these programs until completion of proof-of-concept, at which point we plan to evaluate continued internal development,
partnering or out-licensing.
We
continue to focus on driving profitable growth through expanding our growth catalysts which include: investment in the commercialization
and life cycle management of our commercial Proprietary products, led by CYTOGAM and KEDRAB sales in the U.S. market; continued growth
of our Proprietary hyper-immune portfolio’s revenues in existing and new geographic markets through registration and launch of the
products in new territories; expanding sales of GLASSIA in ex-U.S. markets; generating royalties from GLASSIA sales by Takeda; expanding
our plasma collection capabilities in support of our growing demand for hyper-immune plasma as well as sales of normal source plasma to
other plasma-derived manufacturers; continued increase of our Distribution segment revenues specifically through launching the eleven
biosimilar products in Israel; and leveraging our FDA-approved IgG platform technology, manufacturing, research and development expertise
to advance development and commercialization of additional product candidates, including our investigational Inhaled AAT product, and
identify potential commercial partners for this product.
We
currently expect to generate total revenues for the fiscal year 2023 in the range of $138 million to $146 million and EBITDA in the range
of $22 million to $26 million. The mid- range points of the projected 2023 revenue and EBITDA forecast represent a 10% and 35% growth
over fiscal year 2022, respectively.
Recent Development
On
May 24, 2023, we entered into a share purchase agreement (the “Purchase Agreement”) with FIMI Opportunity Funds (“FIMI”),
the leading private equity firm in Israel and a major shareholder of the Company, to purchase $60 million of our ordinary shares in a
private placement (the “Private Placement”). Under the terms of the Purchase Agreement, Kamada will issue an aggregate of
approximately 12.6 million ordinary shares to FIMI at a price of $4.75 per share (which represents the average closing price of the Company’s
shares on NASDAQ during the 20 trading days prior to the date of the Purchase Agreement). Upon the closing of the transaction, FIMI is
expected to beneficially own approximately 38% of Kamada’s outstanding ordinary shares and will become a controlling shareholder
of the Company, within the meaning of the Israeli Companies Law, 1999 (the “Israeli Companies Law”). Proceeds from the Private
Placement are expected to be used to support the Company’s growth plans and execution of strategic business development opportunities.
At
the extraordinary general meeting of the shareholders of the Company held on August 29, 2023, the Company’s shareholders approved (among
other items), (i) the Private Placement; and (ii) the election of Prof. Benjamin Dekel and Assaf Itshayek as external directors, within
the meaning of the Israeli Companies Law, for an initial three-year term, subject to the closing of the Private Placement. On September
7, 2023, the closing of the Private Placement took place. In connection therewith and unrelated to the registration statement
of which this prospectus forms a part, we agreed to file a registration statement with the SEC registering the resale
of all the ordinary shares held by FIMI, per its request, at any time after the lapse of six months following the closing of the Private
Placement.
On
July 12, 2023, we announced that Kedrion has exercised its option to extend the distribution agreement between the parties in the U.S.
for KEDRAB®. The current agreement now extends through March 2026, and the companies are in discussions to potentially further expand
the scope of the collaboration.
On
August 16, 2023, we announced that we received positive scientific advice from the European Medicines Agency (EMA) regarding the ongoing
pivotal Inhaled AAT study that reconfirms the overall design of the study and acknowledges certain positive results demonstrated in the
previously completed Phase 2/3 study.
Corporate Information
The address of our principal executive office is
2 Holzman St., Science Park, P.O. Box 4081, Rehovot 7670402, Israel, and our telephone number is +972 8 9406472.
RISK FACTORS
Investing in our securities
involves significant risks. Before making an investment decision, you should carefully consider the risks described under “Risk
Factors” in the applicable prospectus supplement and under “Item 3. Key Information – D. Risk Factors” in our
most recent Annual Report on Form 20-F, or any updates in our Reports on Form 6-K, together with all of the other information appearing
in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular
investment objectives and financial circumstances. The risks so described are not the only risks facing us. Additional risks not presently
known to us or that we currently deem immaterial may also impair our business operations. Our business, financial condition and results
of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any
of these risks, and you may lose all or part of your investment. The discussion of risks includes or refers to forward-looking statements;
you should read the explanation of the qualifications and limitations on such forward-looking statements discussed elsewhere in this prospectus.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents
incorporated in it by reference contain forward-looking statements that relate to future events or our future financial performance, which
express the current beliefs and expectations of our management in light of the information currently available to it. Such statements
involve a number of known and unknown risks, uncertainties and other factors that could cause our actual future results, performance or
achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.
Forward-looking statements include all statements that are not historical facts and can be identified by words such as, but without limitation,
“believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,”
“target,” “likely,” “may,” “will,” “would,” or “could,” or other
words, expressions or phrases of similar substance or the negative thereof. We have based these forward-looking statements largely on
our management’s current expectations and future events and financial trends that we believe may affect our financial condition,
results of operation, business strategy and financial needs. You should not rely upon forward-looking statements as predictors of future
events. The occurrence of the events described, and the achievement of the expected results, depend on many events and factors, some or
all of which may not be predictable or within our control. Actual results may differ materially from expected results. See the sections
“Risk Factors” in the applicable prospectus supplement and “Item 3. Key Information – D. Risk Factors” in
our most recent Annual Report on Form 20-F for a more complete discussion of these risks, assumptions and uncertainties and for other
risks, assumptions and uncertainties. These risks, assumptions and uncertainties are not necessarily all of the important factors that
could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable
factors also could harm our results. All of the forward-looking statements we have included in this prospectus and the documents incorporated
in it by reference are based on information available to us on the date of this prospectus. We undertake no obligation, and specifically
decline any obligation, to update publicly or revise any forward-looking statements, whether as a result of new information, future events
or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this prospectus and the
documents incorporated in it by reference might not occur.
REASONS FOR THE OFFER AND USE OF PROCEEDS
Unless otherwise set forth
in the related prospectus supplement or, if applicable, the pricing supplement, we intend to use the net proceeds from the sale of securities
offered through this prospectus for general corporate purposes. The specific purpose of any individual issuance of securities will be
described in the related prospectus supplement.
CAPITALIZATION AND INDEBTEDNESS
Information about our capitalization
and indebtedness will be included in future prospectus supplements (as applicable).
DESCRIPTION OF OUR ORDINARY SHARES
As of September 10, 2023, our authorized share capital consists of
NIS 70,000,000 divided into 70,000,000 Ordinary Shares of a nominal value of NIS 1.0 each, of which 57,474,417 ordinary shares were issued
and outstanding. Under the 2011 Israeli Share Award Plan, as of such date, there were outstanding options for the purchase of an aggregate
of 3,041,971 ordinary shares at a weighted average exercise price of NIS 19.77 (or approximately $5.20) per share and an aggregate of
5,625 restricted share units granted to certain managers of the Company. Under the U.S. Taxpayers Appendix to the 2011 Israeli Share Award
Plan, as of such date, there were outstanding options for the purchase of an aggregate of 240,383 ordinary shares at a weighted average
exercise price of $5.47.
All of our outstanding ordinary
shares are validly issued, fully paid and non-assessable and have equal rights. Our ordinary shares are not redeemable and do not have
any preemptive rights. Pursuant to the Israeli Securities Law, 5728-1968 (“Israeli Securities Law”), a company whose shares
are traded on the Tel Aviv Stock Exchange (the “TASE”) may not have more than one class of shares except for preferred shares
(which may have a dividend preference but may not have any voting rights), all outstanding shares must be validly issued and fully paid
and must be registered for trading on the TASE. The ownership or voting of ordinary shares by non-residents of Israel is not restricted
in any way by our articles of association or the laws of the State of Israel, except for anti-terror legislation and legislation prohibiting
citizens of countries that are, or have been, in a state of war with Israel from being recognized as owners of ordinary shares.
The description below is a
summary of the material provisions of our articles of association and of related material provisions of the Israeli Companies Law.
Ordinary Shares
Voting
Holders of our ordinary shares
have one vote per ordinary share on all matters submitted to a vote of shareholders at a shareholders’ meeting. Shareholders may
vote at shareholder meetings either in person, by proxy or, with respect to certain resolutions, by a voting instrument.
Israeli law does not allow
public companies to adopt shareholder resolutions by means of written consent in lieu of a shareholder meeting.
Transfer of Shares
Fully paid ordinary shares
are issued in registered form and may be freely transferred under our articles of association unless the transfer is restricted or prohibited
by another instrument, Israeli law or the rules of a stock exchange on which the shares are traded.
Election of Directors
Our ordinary shares do not
have cumulative voting rights for the election of directors. Rather, under our articles of association, directors (other than external
directors, if any) are elected by the holders of a simple majority of our ordinary shares at a general shareholder meeting (excluding
abstentions). As a result, the holders of our ordinary shares that represent more than 50% of the voting power represented at a shareholder
meeting and voting thereon (excluding abstentions) have the power to elect any or all of our directors (other than external directors,
if any) whose positions are being filled at that meeting. Directors (other than external directors) serve until the annual meeting of
shareholders following the shareholder meeting at which they were elected (or until such director ceases to serve in such capacity, if
earlier).
External directors are elected
for three-year terms each and their election requires the affirmative vote of the holders of a majority of the ordinary shares represented
at a meeting of shareholders, subject to the fulfillment of one of the following additional voting requirements: (i) the shares voting
in favor of the election of an external director (excluding abstentions) include at least a majority of the shares voted by shareholders
who are not controlling shareholders and shareholders who do not have a personal interest (within the meaning of the Israeli Companies
Law) in such election (excluding a personal interest that is not related to a relationship with a controlling shareholder), or (ii) the
total number of shares voted against the election by shareholders referred to in clause (i) does not exceed two-percent (2%) of our outstanding
voting rights.
In addition, under our articles
of association, vacancies on our board of directors, including vacancies resulting from there being fewer than the maximum number of directors
permitted by our articles of association, may be filled by a vote of a simple majority of the directors then in office, and such appointment
shall be valid until the next annual general meeting (or until such director ceases to serve in such capacity, if earlier).
Dividend and Liquidation Rights
Under Israeli law, we may
declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution
will prevent us from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Israeli Companies
Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years
legally available for distribution according to our then last reviewed or audited financial statements, after subtracting earlier distributions
if they have not yet been subtracted from the earnings, provided that the date of the financial statements is not more than six months
prior to the date of distribution. In the event that we do not have retained earnings or earnings generated over the two most recent years
legally available for distribution, we may seek the approval of the court in order to distribute a dividend. The court may approve our
request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying our existing
and foreseeable obligations as they become due.
In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of ordinary shares in proportion to the
nominal value of their shareholdings. Dividend and liquidation rights may be affected by the grant of preferential dividend or distribution
rights to the holders of a class of shares with preferential rights that may be authorized in the future (subject to applicable law and
applicable stock exchange rules).
Shareholder Meetings
Under the Israeli Companies
Law, we are required to convene an annual general meeting of our shareholders at least once every calendar year and within a period of
not more than 15 months following the preceding annual general meeting. Our board of directors may convene a special general meeting of
our shareholders whenever it sees fit and is required to do so upon the written request of two directors or one quarter of the serving
members of our board of directors, or one or more holders of 5% or more of our outstanding share capital and 1% of our voting power, or
the holder or holders of 5% or more of our voting power.
The Israeli Companies Law
requires that resolutions regarding the following matters (among others) be approved by our shareholders at a general meeting: amendments
to our articles of association; appointment, terms of service and termination of service of our auditors; election of external directors;
approval of certain related party transactions; increases or reductions of our authorized share capital; mergers; and the exercise of
our board of director’s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise
of any of its powers is essential for our proper management.
The
chairman of our board of directors presides over our general meetings. However, if at any general meeting the chairman is not present
within 15 minutes after the appointed time, or is unwilling to act as chairman of such meeting, then the shareholders present will choose
any other person present to be chairman of the meeting. Subject to the provisions of the Israeli Companies Law and the regulations promulgated
thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by
the board of directors, which, as company listed also on an exchange outside of Israel, may be between four and 40 days prior to the date
of the meeting.
Israeli
law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior
to the meeting and if the agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of
transactions with office holders or interested or related parties, an approval of a merger or the approval of the compensation policy,
notice must be provided at least 35 days prior to the meeting.
Quorum
Pursuant
to our articles of association, the quorum required for a meeting of our shareholders is
the presence of two or more shareholders present in person, by proxy or by a voting instrument, who hold at least 25% of our voting power.
A meeting adjourned for lack of a quorum is generally adjourned to one week thereafter at the same time and place, or to such other day,
time and place, as our board of directors may indicate in the notice of the meeting to the shareholders. Pursuant to our articles of association,
at the reconvened meeting, the meeting will take place with whatever number of participants present.
Resolutions
Under
the Israeli Companies Law, unless otherwise provided in our articles of association or applicable law, all resolutions of the shareholders
require a simple majority of the voting rights represented at the meeting, in person, by proxy or, with respect to certain resolutions,
by a voting instrument, and voting on the resolution (excluding abstentions). Under Israeli law, a resolution for the voluntary winding
up of the company requires the approval by the holders of 75% of the voting rights represented at the meeting, in person or by proxy and
voting on the resolution (excluding abstentions). Under our articles of association, a merger shall require the approval of a special
majority of the shareholders, as described below under “Merger.”
Access to Corporate Records
Under
the Israeli Companies Law, all shareholders generally have the right to review minutes of
our general meetings, our shareholder register and register of significant shareholders (as defined in the Israeli Companies Law), our
articles of association, our financial statements and any document we are required by law to file publicly with the Israeli Companies
Registrar or with the Israel Securities Authority. In addition, any shareholder who specifies the purpose of its request may request to
review any document in our possession that relates to: (i) any action or transaction with a related party which requires shareholder approval
under the Israeli Companies Law; or (ii) the approval, by the board of directors, of an action in which an office holder has a personal
interest. We may deny a request to review a document if we determine that the request was not made in good faith, that the document contains
a commercial or technological secret or that the document’s disclosure may otherwise impair our interests.
Acquisitions Under Israeli Law
Full Tender Offer
A
person wishing to acquire shares of an Israeli public company and who would, as a result, hold over 90% of the target company’s
issued and outstanding share capital (or over 90% of the issued and outstanding share capital of a certain class of shares) is required
by the Israeli Companies Law to make a tender offer to all of the company’s shareholders (or all of the shareholders who hold shares
of the same class) for the purchase of all of the issued and outstanding shares of the company or of a certain class. If the shareholders
who do not respond to or accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class of the shares, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of
the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will
also be accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of the shares.
Upon
a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to
determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However,
under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be
entitled to petition the Israeli court as described above.
If
(a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the
company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not
have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not
accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer
may not acquire shares of the company that will increase its holdings to more than 90% of the company’s issued and outstanding share
capital or of the applicable class from shareholders who accepted the tender offer.
Special Tender Offer
The
Israeli Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer
if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This rule does
not apply if there is already another holder of 25% or more of the voting rights in the company.
Similarly,
the Israeli Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if
as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, provided there
is no other shareholder of the company who holds more than 45% of the voting rights in the company.
These
requirements do not apply if the acquisition (i) occurs in the context of a private placement, that was approved by the company’s
shareholders and whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person who holds
25% or more of the voting rights in the company, or as a private placement whose purpose is to give the acquirer 45% of the voting rights
in the company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a shareholder holding 25% or more
of the voting rights in the company and resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company;
or (iii) was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming a holder of more
than 45% of the voting rights in the company.
A
special tender offer must be extended to all shareholders of a company. The special tender offer may be consummated only if (i) at least
5% of the voting power attached to the company’s outstanding shares will be acquired by the offeror, and (ii) the number of shares
tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding controlling shareholders, holders of
25% or more of the voting rights in the company and any person having a personal interest in the acceptance of the tender offer).
In
the event that a special tender offer is made, a company’s board of directors is required to express its opinion on the advisability
of the offer or it may abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention.
An
office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause
the failure of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential
purchaser and shareholders for damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds
to believe he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with the potential
purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a
competing offer.
If
a special tender offer is accepted, then shareholders who did not respond to the special offer or had objected to the special tender offer
may accept the offer within four days of the last day set for the acceptance of the offer.
In
the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it and any corporation controlled
by them must refrain from making a subsequent tender offer for the purchase of shares of the target company and may not effect a merger
with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to
effect such an offer or merger in the initial special tender offer.
Merger
The
Israeli Companies Law permits merger transactions if approved by each party’s board of directors and, unless certain requirements
described under the Israeli Companies Law are met, a majority of each party’s shareholders. Under our articles of association, a
merger shall require the approval of 66.6% of the voting rights represented at a meeting of our shareholders and voting on the matter,
in person or by proxy, and any amendment to such provision shall require the approval of 60% of the voting rights represented at a meeting
of our shareholders and voting on the matter, in person or by proxy.
The
board of directors of a merging company is required pursuant to the Israeli Companies Law to discuss and determine whether in its opinion
there exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations
towards its creditors, taking into account the financial condition of the merging companies. If the board of directors has determined
that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging
companies, the boards of directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.
For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares voting at the shareholders meeting
(excluding abstentions) that are held by parties other than the other party to the merger, any person who holds 25% or more of the outstanding
shares or the right to appoint 25% or more of the directors of the other party, or any one on their behalf including their relatives or
corporations controlled by any of them, vote against the merger.
In addition, if the non-surviving
entity of the merger has more than one class of shares, the merger must be approved by each class of shareholders.
If the transaction would have
been approved but for the separate approval of each class of shares or the exclusion of the votes of certain shareholders as provided
above, a court may still rule that the company has approved the merger upon the request of holders of at least 25% of the voting rights
of a company, if the court holds that the merger is fair and reasonable, taking into account the appraisal of the merging companies’
value and the consideration offered to the shareholders.
Under the Israeli Companies
Law, a merging company must send a copy of the proposed merger plan to its secured creditors no later than three days after the date on
which the merger proposal was submitted to the Israeli Companies Registrar. Unsecured creditors are entitled to receive notice of the
merger, as provided by the regulations promulgated under the Israeli Companies Law. Upon the request of a creditor of a merging company,
the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the
surviving company will be unable to satisfy the obligations of the target company. The court may also give instructions in order to secure
the rights of creditors.
In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed with the Israeli
Registrar of Companies and 30 days from the date that shareholder approval of both merging companies was obtained.
Anti-Takeover Measures under Israeli Law
The
Israeli Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including
shares providing certain preferred or additional rights to voting, distributions or other matters and shares having preemptive rights.
We do not have any authorized or issued shares other than ordinary shares. In the future, if we do create and issue a class of shares
other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent
a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The
authorization of a new class of shares will require an amendment to our articles of association which requires the prior approval of a
majority of our shares represented and voting at a general meeting. Shareholders voting at such
a meeting will be subject to the restrictions under the Israeli Companies Law described above in “— Ordinary Shares —
Voting.” Pursuant to the Israeli Securities Law, a company whose shares are traded on the TASE may not have more than one
class of shares except for preferred shares which may have a dividend preference but may not have any voting rights.
Tax Law
Israeli tax law treats some
acquisitions, such as stock-for-stock swaps between an Israeli company and a foreign company, less favorably than U.S. tax law. For example,
Israeli tax law may subject a shareholder who exchanges ordinary shares in an Israeli company for shares in a non-Israeli corporation
to immediate taxation unless such shareholder receives authorization from the Israel Tax Authority for different tax treatment.
Modification of Class Rights
The Israeli Companies Law
and our articles of association provide that the rights of a particular class of shares may not be modified without the affirmative vote
at a separate meeting of such class of a majority of shares actually participating in such class meeting.
Establishment
We
were incorporated under the laws of the State of Israel on December 13, 1990 under the name
Kamada Ltd. We are registered with the Israeli Registrar of Companies in Jerusalem. Our registration number is 51-152460-5. Our purpose
as set forth in our amended and restated articles of association is to engage in any lawful business.
Transfer Agent and Registrar
The
transfer agent and registrar for our ordinary shares is American Stock Transfer & Trust
Company, LLC. The nominee company to the TASE in whose name most of our outstanding shares are held of record is Mizrahi Tefahot Registration
Company Ltd.
Listing
Our ordinary shares are
listed on the TASE and Nasdaq Global Select Market under the symbol “KMDA.”
PLAN OF DISTRIBUTION
We may sell the ordinary
shares from time to time pursuant to underwritten public offerings, “at-the-market” offerings as defined in Rule 415 at negotiated
prices, negotiated transactions, block trades or a combination of these methods or through underwriters or dealers, through agents and/or
directly to one or more purchasers. The ordinary shares may be distributed from time to time in one
or more transactions:
| ● | at
a fixed price or prices, which may be changed; |
| | |
| ● | at
market prices prevailing at the time of sale; |
| | |
| ● | at
prices related to such prevailing market prices; or |
| | |
Each time that we sell ordinary
shares covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution
and set forth the terms and conditions of the offering of such ordinary shares, including to the extent applicable:
| ● | the
name or names of any underwriters, dealers or agents, if any; |
| | |
| ● | the
purchase price of the securities and the proceeds we received from the sale; |
| | |
| ● | any
over-allotment options under which underwriters may purchase additional securities from us; |
| | |
| ● | any
agency fees or underwriting discounts and other items constituting agents’ or underwriters’
compensation; |
| | |
| ● | any
public offering price; |
| | |
| ● | any
discounts or concessions allowed or reallowed or paid to dealers; and |
| ● | any
securities exchange or market on which the securities may be listed. |
Offers to purchase the ordinary
shares being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities
from time to time.
Offers to purchase the ordinary
shares being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities
from time to time.
If a dealer is utilized in
the sale of the ordinary shares being offered by this prospectus, the ordinary shares will be sold to the dealer, as principal. The dealer
may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.
If an underwriter is utilized
in the sale of the ordinary shares being offered by this prospectus, an underwriting agreement will be executed with the underwriter at
the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales
of the securities to the public. In connection with the sale of the ordinary shares, we or the purchasers of ordinary shares for whom
the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter
may sell the ordinary shares to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or
commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. We may offer the securities
to the public through underwriting syndicates represented by managing underwriters or underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all of the securities offered by a prospectus supplement. Any public offering
price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with
whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.
Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase ordinary
shares as a principal, and may then resell the ordinary shares at varying prices to be determined by the dealer.
Any compensation paid to underwriters,
dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters
to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the
distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and commissions
received by them and any profit realized by them on resale of the ordinary shares may be deemed to be underwriting discounts and commissions.
We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the
Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain
expenses.
Our ordinary shares are traded
on the Nasdaq Global Select Market and the TASE under the symbol “KMDA.” To facilitate the offering of securities, certain
persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities.
This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of
more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making
purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain
the price of the ordinary shares by bidding for or purchasing ordinary shares in the open market or by imposing penalty bids, whereby
selling concessions allowed to dealers participating in the offering may be reclaimed if ordinary shares sold by them are repurchased
in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the
ordinary shares at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any
time.
We may authorize agents or
underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price
set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in
the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in
the prospectus supplement.
We may engage in at the market
offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative
transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions.
If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered
by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities
pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities
received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions
will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective
amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell
the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may
transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities.
We may provide agents, underwriters
and dealers with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect
to payments that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or
their respective affiliates, may engage in transactions with, or perform services for, us in the ordinary course of business.
The underwriters, dealers
and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation.
EXPENSES
We are paying all of the expenses of the registration
of our securities under the Securities Act, including, to the extent applicable, registration and filing fees, printing and duplication
expenses, administrative expenses, accounting fees and the legal fees of our counsel. We estimate these expenses to be approximately $34,010
which at the present time include the following categories of expenses:
SEC registration fee | |
$ | 5,510 | |
Legal fees and expenses | |
$ | 18,500 | |
Accounting fees and expenses | |
$ | 10,000 | |
Miscellaneous expenses | |
$ | 600 | |
Total | |
$ | 34,610 | |
In addition, we anticipate incurring additional
expenses in the future in connection with the offering of our securities pursuant to this prospectus. Any such additional expenses will
be disclosed in a prospectus supplement.
LEGAL
MATTERS
The
validity of the ordinary shares and certain other legal matters as to Israeli law will be passed upon for us by FISCHER (FBC & Co.),
Tel Aviv, Israel. Certain legal matters as to United States law will be passed upon for us by Morrison & Foerster LLP, San Francisco,
California.
EXPERTS
The
consolidated financial statements of Kamada Ltd. appearing in Kamada Ltd.’s Annual Report (Form 20-F) for the year ended December
31, 2022 and the effectiveness of Kamada Ltd.’s internal control over financial reporting as of December 31, 2022, have been audited
by Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, an independent registered public accounting firm, as set forth
in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated
herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement on Form F-3 under the Securities Act, with respect to the securities offered by this
prospectus. This prospectus and any accompanying prospectus supplement do not contain all the information contained in the registration
statement, including its exhibits and schedules. You should refer to the registration statement, including the exhibits and schedules,
for further information about us and the securities we may offer. Statements we make in this prospectus and any accompanying prospectus
supplement about certain contracts or other documents are not necessarily complete. When we make such statements, we refer you to the
copies of the contracts or documents that are filed as exhibits to the registration statement, because those statements are qualified
in all respects by reference to those exhibits. The registration statement, including exhibits and schedules, is on file at the office
of the SEC and may be inspected without charge.
We
are subject to the information reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”)
applicable to foreign private issuers. Under the Exchange Act, we are required to file reports, including annual reports, and other information
with the SEC. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content
of proxy statements and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
and current reports and financial statements as frequently or as promptly as U.S. companies whose securities are registered under the
Exchange Act. However, we file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by
the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and
we submit to the SEC, on Form 6-K, unaudited quarterly financial information. The SEC maintains a website that contains reports and other
information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov.
Our
website address is www.kamada.com. The reference to our website is intended to be an inactive
textual reference and the information on, or accessible through, our website is not intended to be part of this prospectus.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” into this prospectus the information in documents we file with it. This means
that we can disclose important information to you by referring you another document filed by us with the SEC. Each document incorporated
by reference is current only as of the date of such document, and the incorporation by reference of such documents shall not create any
implication that there has been no change in our affairs since the date thereof or that the information contained therein is current
as of any time subsequent to its date. The information incorporated by reference is considered to be a part of this prospectus and should
be read with the same care. When we update the information contained in documents that have been incorporated by reference by making
future filings with the SEC, the information incorporated by reference in this prospectus is considered to be automatically updated and
superseded. In other words, in the case of a conflict or inconsistency between information contained in this prospectus and information
incorporated by reference into this prospectus, you should rely on the information contained in the document that was filed later.
We
incorporate by reference into this prospectus documents listed below and any future filings made with the SEC under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, and, to the extent specifically designated therein, reports on Form 6-K we furnish to the SEC on or
after the date on which this registration statement is first filed with the SEC, and until the termination or completion of that offering
under this prospectus:
| ● | our
annual report on Form 20-F for the fiscal year ended December 31, 2022; |
| ● | our
report on Form 6-K furnished to the SEC on March 15,2023, May 3, 2023, May 16, 2023, May 24, 2023 (three reports), July 12, 2023, July 13, 2023, August 9, 2023, August 16, 2023 and
August 30, 2023; |
| ● | our
report on Form 6-K/A furnished to the SEC on May 24, 2023; and |
| ● | the
description of our ordinary shares contained under the heading “Item 1. Description
of Registrant’s Securities to be Registered” in our registration statement on
Form 8-A, as filed with the SEC on May 28, 2013, including any subsequent amendment or any
report filed for the purpose of updating such description. |
Any
statement contained herein or in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein
shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein
or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this registration statement.
Unless
expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to,
but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents
unless such exhibits are specially incorporated by reference in this prospectus, will be provided at no cost to each person, including
any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to:
Kamada
Ltd.
c/o
Amir London, Chief Executive Officer
2
Holzman Street
Science
Park
P.O.
Box 4081
Rehovot
7670402
Tel:
+972 8 9406472
ENFORCEABILITY
OF CIVIL LIABILITIES
We
are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli
experts named in this prospectus, substantially all of whom reside outside the United States, may be difficult to obtain within the United
States. Furthermore, because the majority of our assets and substantially all of our directors and officers and the Israeli experts named
in this prospectus are located outside the United States, any judgment obtained in the United States against us or any of these persons
may be difficult to collect within the United States.
We
have irrevocably appointed Puglisi & Associates as our agent to receive service of process in any action against us in any United
States federal or state court. The address of Puglisi & Associates is 850 Library Avenue, Suite 204, P.O. Box 885, Newark, Delaware
19715.
We
have been informed by our legal counsel in Israel, FISCHER (FBC & Co.), that it may be difficult to initiate an action with
respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities
laws, on the grounds that Israel is not the most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees
to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable,
the content of applicable United States law must be proved as a fact by expert witnesses, which can be a time-consuming and costly process.
Certain matters of procedure may also be governed by Israeli law.
Subject
to certain time limitations, legal procedures and exceptions, Israeli courts may enforce a U.S. judgment in a civil matter which is non-appealable,
including a judgment based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or
compensatory judgment in a non-civil matter, provided that, among other things:
| ● | the
judgment was rendered by a court which was, according to the laws of the state of the court,
competent to render the judgment; |
| ● | the
obligation imposed by the judgment is enforceable according to the rules relating to the
enforceability of judgments in Israel and the substance of the judgment is not contrary to
public policy; and |
| ● | the
judgment is executory in the state in which it was given. |
Even
if such conditions are met, an Israeli court may not declare a foreign civil judgment enforceable if:
| ● | the
judgment was given in a state whose laws do not provide for the enforcement of judgments
of Israeli courts (subject to exceptional cases); |
| ● | the
enforcement of the judgment is likely to prejudice the sovereignty or security of the State
of Israel; |
| ● | the
judgment was obtained by fraud; |
| ● | the
opportunity given to the defendant to bring its arguments and evidence before the court was
not reasonable in the opinion of the Israeli court; |
| ● | the
judgment was rendered by a court not competent to render it according to the laws of private
international law as they apply in Israel; |
| ● | the
judgment is contradictory to another judgment that was given in the same matter between the
same parties and that is still valid; or |
| ● | at
the time the action was brought in the foreign court, a lawsuit in the same matter and between
the same parties was pending before a court or tribunal in Israel. |
If
a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into
non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a
non-Israeli currency is for the Israeli court to render a judgment for the equivalent amount in Israeli currency at the rate of exchange
in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of
the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest
at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable
exchange rates.
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item 8.
Exculpation, Insurance and Indemnification of Directors and Officers
Under
the Israeli Companies Law, 5759-7999 (the “Israeli Companies Law”), a company may not exculpate an office holder from liability
for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole
or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation
is included in the company’s articles of association. Our articles of association include such a provision. However, pursuant our
articles of association, we may not exculpate an office holder for an action or transaction in which a controlling shareholder or any
other office holder (including an office holder who is not the office holder we have undertaken to exculpate) has a personal interest
(within the meaning of the Israeli Companies Law). We may also not exculpate in advance a director from liability arising out of a prohibited
dividend or distribution to shareholders.
Under
the Israeli Companies Law, a company may indemnify an office holder for the following liabilities, payments and expenses incurred for
acts performed by him or her, as an office holder, either pursuant to an undertaking given by the company in advance of the act or following
the act, provided its articles of association authorize such indemnification:
| ● | a
monetary liability imposed on him or her in favor of another person pursuant to a judgment,
including a settlement or arbitrator’s award approved by a court. However, if an undertaking
to indemnify an office holder with respect to such liability is provided in advance, then
such an undertaking must be limited to events which, in the opinion of the board of directors,
can be foreseen based on the company’s activities when the undertaking to indemnify
is given, and to an amount, or according to criteria, determined by the board of directors
as reasonable under the circumstances. Such undertaking shall detail the foreseen events
and amount or criteria mentioned above; |
| ● | reasonable
litigation expenses, including reasonable attorneys’ fees, incurred by the office holder
(1) as a result of an investigation or proceeding instituted against him or her by an authority
authorized to conduct such investigation or proceeding, provided that (i) no indictment was
filed against such office holder as a result of such investigation or proceeding; and (ii)
no financial liability was imposed upon him or her as a substitute for the criminal proceeding
as a result of such investigation or proceeding or, if such financial liability was imposed,
it was imposed with respect to an offense that does not require proof of criminal intent
(mens rea); and (2) in connection with a monetary sanction; and |
| ● | reasonable
litigation expenses, including attorneys’ fees, incurred by the office holder or imposed
by a court in proceedings instituted against him or her by the company, on its behalf, or
by a third party, or in connection with criminal proceedings in which the office holder was
acquitted, or as a result of a conviction for an offense that does not require proof of criminal
intent (mens rea). |
In
addition, under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts
performed by him or her as an office holder, to the extent provided in the company’s articles of association:
| ● | a
breach of a duty of loyalty to the company, provided that the office holder acted in good
faith and had a reasonable basis to believe that the act would not harm the company; |
| ● | a
breach of duty of care to the company or to a third party, to the extent such a breach arises
out of the negligent conduct of the office holder; and |
| ● | a
monetary liability imposed on the office holder in favor of a third party. |
Under
the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:
| ● | a
breach of the duty of loyalty, except for indemnification and insurance for a breach of the
duty of loyalty to the company to the extent that the office holder acted in good faith and
had a reasonable basis to believe that the act would not harm the company; |
| ● | a
breach of the duty of care committed intentionally or recklessly, excluding a breach arising
out of the negligent conduct of the office holder; |
| ● | an
act or omission committed with intent to derive illegal personal benefit; or |
| ● | a
fine or penalty levied against the office holder. |
Our
articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted under the Israeli
Companies Law (other than indemnification for litigation expenses in connection with a monetary sanction); provided that we may not exculpate
an office holder for an action or transaction in which a controlling shareholder or any other office holder (including an office holder
who is not the office holder we have undertaken to exculpate) has a personal interest (within the meaning of the Israeli Companies Law).
We
have entered into indemnification and exculpation agreements with each of our current office holders exculpating them from a breach of
their duty of care to us to the fullest extent permitted by the Israeli Companies Law (provided that we may not exculpate an office holder
for an action or transaction in which a controlling shareholder or any other office holder (including an office holder who is not the
office holder we have undertaken to exculpate) has a personal interest (within the meaning of the Israeli Companies Law)) and undertaking
to indemnify them to the fullest extent permitted by the Israeli Companies Law (other than indemnification for litigation expenses in
connection with a monetary sanction), to the extent that these liabilities are not covered by insurance. This indemnification is limited
to events determined as foreseeable by our board of directors based on our activities, as set forth in the indemnification agreements.
Under such agreements, the maximum aggregate amount of indemnification that we may pay to all of our office holders together is (i) for
office holders who joined our company before May 31, 2013, the greater of 30% of the shareholders equity according to our most recent
financial statements (audited or reviewed) at the time of payment and NIS 20 million, and (ii) for office holders who joined our company
after May 31, 2013, 25% of the shareholders equity according to our most recent financial statements (audited or reviewed) at the time
of payment.
We
are not aware of any pending or threatened litigation or proceeding involving any of our office holders as to which indemnification is
being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any office holder.
Item 9.
Exhibits
Exhibit
Number |
|
Description |
|
|
|
1.1* |
|
Form of underwriting agreement. |
|
|
|
4.1 |
|
Amended Articles of Association of the Registrant (incorporated by reference to Appendix A2 to the Proxy Statement for the 2016 Annual General Meeting of Shareholders, filed as Exhibit 99.1 to Form 6-K filed with the Securities and Exchange Commission on July 26, 2016). |
|
|
|
4.2 |
|
Memorandum of Association of the Registrant, as currently in effect (as translated from Hebrew) (incorporated by reference to Exhibit 3.2 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on May 15, 2013). |
|
|
|
4.3 |
|
Form of Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.1 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on May 15, 2013). |
|
|
|
4.4 |
|
Share Purchase Agreement dated as of January 20, 2020, by and among Kamada Ltd. and the FIMI Funds (incorporated by reference to Exhibit 99.2 to Form 6-K filed with the Securities and Exchange Commission on January 21, 2020). |
|
|
|
4.5 |
|
Registration Rights Agreement, dated as of January 20, 2020, by and among Kamada Ltd. and the FIMI Funds (incorporated by reference to Exhibit 99.3 to Form 6-K filed with the Securities and Exchange Commission on January 21, 2020). |
|
|
|
4.6 |
|
Share Purchase Agreement dated as of May 23, 2023, by and among Kamada Ltd. and the FIMI Funds (incorporated by reference to Exhibit 99.2 to Form 6-K/A filed with the Securities and Exchange Commission on May 24, 2023). |
|
|
|
4.7 |
|
Registration Rights Agreement, dated as of May 23, 2023, by and among Kamada Ltd. and the FIMI Funds (incorporated by reference to Exhibit 99.3 to Form 6-K/A filed with the Securities and Exchange Commission on May 24, 2023). |
|
|
|
5.1** |
|
Opinion of FISCHER (FBC & Co.) |
|
|
|
23.1** |
|
Consent of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, an independent registered public accounting firm for Kamada Ltd. |
|
|
|
23.2** |
|
Consent of FISCHER (FBC & Co.) (included in Exhibit 5.1). |
|
|
|
24 |
|
Power of Attorney (included in the signature page of this registration statement). |
|
|
|
107** |
|
Calculation of Filing Fee Tables |
| * | To
be filed, if applicable, by post-effective amendment or incorporated by reference in connection
with the offering of any ordinary shares, as appropriate. |
Item
10. Undertakings
(a)
The undersigned registrant hereby undertakes:
(1)
to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by section 10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration
Fee” table in the effective registration statement;
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii)
of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act
that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b)
that is part of the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4)
To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F
at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by
Section 10(a)(3) of the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of a
post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that
all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing,
a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities
Act or Item 8.A. of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished
to the SEC by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in this registration
statement.
(5)
That, for the purpose of determining liability under the Securities Act to any purchaser:
(i)
If the registrant is relying on Rule 430B:
(A)
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and
(B)
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required
by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of
the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering
described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement
to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. Provided, however , that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in
any such document immediately prior to such effective date; or
(ii)
If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall
be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
however , that no statement made in a registration statement or prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was
made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such date of first use.
(6)
That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities:
The
undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:
| (i) | Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering
required to be filed pursuant to Rule 424; |
| (ii) | Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned
registrant or used or referred to by the undersigned registrant; |
| (iii) | The
portion of any other free writing prospectus relating to the offering containing material
information about the undersigned registrant or its securities provided by or on behalf of
the undersigned registrant; and |
| (iv) | Any
other communication that is an offer in the offering made by the undersigned registrant to
the purchaser. |
(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of
the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act (and, where applicable, each filing
of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act) that is incorporated by reference
in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.
(d)
The undersigned registrant hereby undertakes that:
(1)
For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule
424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was
declared effective.
(2)
For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.
SIGNATURES
Pursuant
to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunder
duly authorized, in Rehovot, Israel, on September 11, 2023.
|
KAMADA LTD. |
|
|
|
|
By: |
/s/ Amir London |
|
|
Amir London, Chief Executive Officer |
POWER
OF ATTORNEY
We,
the undersigned directors and/or officers of Kamada Ltd., hereby severally constitute and appoint Amir London and Chaime Orlev, and each
of them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our
names in the capacities indicated below the registration statement on Form F-3 filed herewith, and any and all pre-effective and post-effective
amendments to said registration statement, and any registration statement filed pursuant to Rule 462(b) under the Securities Act, as
amended, in connection with the said registration under the Securities Act, as amended, and to file or cause to be filed the same, with
all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys, and each of them, full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully
to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys,
and each of them, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant
to the requirements of the Securities Act, as amended, this registration statement has been signed below by the following persons in
the capacities and on the dates indicated:
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/
Amir London |
|
Chief
Executive Officer
|
|
September 11, 2023 |
Amir London |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Chaime
Orlev |
|
Chief
Financial Officer
|
|
September 11, 2023 |
Chaime Orlev |
|
(Principal Financial Officer and Principal
Accounting Officer) |
|
|
|
|
|
|
|
/s/ Lilach
Asher-Topilsky |
|
Chairman of the Board |
|
September 11, 2023 |
Lilach Asher-Topilsky |
|
|
|
|
|
|
|
|
|
/s/ Uri Botzer |
|
Director |
|
September 11, 2023 |
Uri Botzer |
|
|
|
|
|
|
|
|
|
/s/ Ishay
Davidi |
|
Director |
|
September 11, 2023 |
Ishay Davidi |
|
|
|
|
|
|
|
|
|
/s/ Karnit
Goldwasser |
|
Director |
|
September 11, 2023 |
Karnit Goldwasser |
|
|
|
|
|
|
|
|
|
/s/ Jonathan
Hahn |
|
Director |
|
September 11, 2023 |
Jonathan Hahn |
|
|
|
|
|
|
|
|
|
/s/ Lilach
Payorski |
|
Director |
|
September 11, 2023 |
Lilach Payorski |
|
|
|
|
|
|
|
|
|
/s/ Leon Recanati |
|
Director |
|
September 11, 2023 |
Leon Recanati |
|
|
|
|
|
|
|
|
|
/s/ Prof.
Ari Shamiss |
|
Director |
|
September 11, 2023 |
Prof. Ari Shamiss |
|
|
|
|
|
|
|
|
|
/s/ David
Tsur |
|
Director |
|
September 11, 2023 |
David Tsur |
|
|
|
|
|
|
|
|
|
/s/ Prof.
Benjamin Dekel |
|
Director |
|
September 11, 2023 |
Prof. Benjamin Dekel |
|
|
|
|
|
|
|
|
|
/s/ Assaf
Itshayek |
|
Director |
|
September 11, 2023 |
Assaf Itshayek |
|
|
|
|
SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant
to the requirements of the Securities Act, as amended, the undersigned, the duly authorized representative in the United States of Kamada
Ltd. has signed this registration statement on September 11, 2023.
|
PUGLISI & ASSOCIATES |
|
|
|
|
By: |
/s/ PUGLISI & ASSOCIATES |
|
Name: |
Donald J. Puglisi |
|
Title: |
Managing Director |
Exhibit 5.1
|
Tel. 972-3-69441111 |
|
Fax. 972-3-6091116 |
|
fbc@fbclawyers.com |
September 11, 2023
To:
Kamada Ltd.
Sapir St.
Kiryat Weizmann Science Park
P.O. Box 4081
Ness Ziona 74140
Israel
Re: Kamada Ltd.
Ladies and Gentlemen:
We have acted as Israeli counsel
to Kamada Ltd., a company organized under the laws of the State of Israel (the “Company”), in connection with the registration
statement on Form F-3 to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) pursuant
to the U.S. Securities Act of 1933, as amended (the “Securities Act”) (the “Registration Statement”),
which registers the offer and sale by the Company, from time to time, of up to $50,000,000, in the aggregate, of ordinary shares, par
value NIS 1.00 per share (“Ordinary Shares”) of the Company (the “Shares”)
This opinion letter is furnished
to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, in connection
with the filing of the Registration Statement.
In connection herewith, we have
examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the form of the Registration
Statement, to which this opinion letter is attached as an exhibit; (ii) a copy of the articles of association of the Company, as amended
and currently in effect (the “Articles”); (iii) resolutions of the board of directors of the Company (the “Board”)
that relate to the Registration Statement and the actions to be taken in connection therewith; and (iv) such other corporate records,
agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives
of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of
such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.
In such examination, we
have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents
submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified
copies and the authenticity of the originals of such latter documents. We have assumed the same to have been properly given and to
be accurate. We have also assumed the truth of all facts communicated to us by the Company and that all consents and minutes of
meetings of committees of the Board, the Board and the shareholders of the Company that have been provided to us are true and
accurate and have been properly prepared in accordance with the Articles and all applicable laws. We have assumed, in addition, that
at the time of the execution and delivery of any definitive purchase, underwriting or similar agreement between the Company and any
third party pursuant to which any of the Shares may be issued (a “Securities Agreement”), the Securities
Agreement will be the valid and legally binding obligation of such third party, enforceable against such third party in accordance
with its terms. We have further assumed that at the time of the issuance and sale of any of the Shares, the terms of the Shares, and
the issuance and sale thereof, will have been established so as not to violate any applicable law or result in a default under or
breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or restriction imposed by
any court or governmental body having jurisdiction over the Company.
Based upon and subject to the
foregoing, we are of the opinion that assuming (a) the taking of all necessary corporate action to authorize and approve the issuance
of any Shares, the terms of the offering thereof and related matters (the “Authorizing Resolutions”), (b) the effectiveness
of the Registration Statement (including any post-effective amendments) under the Securities Act, and that such effectiveness shall not
have been terminated or rescinded, (c) the delivery and filing of an appropriate prospectus supplement with respect to the offering of
the Shares in compliance with the Securities Act and the applicable rules and regulations thereunder, (d) approval by the Board of, and
entry by the Company into, and performance by the Company under, any applicable Securities Agreement, in the form filed as an exhibit
to the Registration Statement, any post-effective amendment thereto or to a Report of Foreign Private Issuer on Form 6-K, pursuant to
which the Shares may be issued and sold, (e) at the time of issuance and sale of the Shares, a sufficient number of Ordinary Shares shall
be authorized and available for issuance under the Articles as then in effect and that the consideration for the issuance and sale of
the Shares is in an amount that is not less than the nominal (par) value of the Shares, and (f) receipt by the Company of the consideration
for the Shares as provided for in the Authorizing Resolutions and in accordance with the provisions of any such Securities Agreement,
the Shares will be validly issued, fully paid and non-assessable.
You have informed us that you
intend to issue the Shares from time to time on a delayed or continuous basis, and this opinion is limited to the laws, including the
rules and regulations, as in effect on the date hereof. We understand that prior to issuing any Shares you will afford us an opportunity
to review the corporate approval documents and operative documents pursuant to which such Shares are to be issued (including an appropriate
prospectus supplement), and we will file such supplement or amendment to this opinion (if any) as we may reasonably consider necessary
or appropriate by reason of the terms of such Shares.
Members of our firm are admitted
to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion
is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.
We hereby consent to the filing
of this opinion as an exhibit to the Registration Statement and to the reference to our firm appearing under the caption “Legal
Matters” and “Enforceability of Civil Liabilities” in the prospectus constituting part of the Registration Statement.
In giving this consent, we do not thereby admit that we are an “expert” within the meaning of the Securities Act.
This opinion letter is rendered
as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought
to our attention after the date hereof that may alter, affect or modify the opinions expressed herein.
|
Very truly
yours, |
|
|
|
/s/
FISCHER (FBC & Co.) |
|
FISCHER (FBC & Co.) |
3
Exhibit 23.1
Consent of Independent Registered Public Accounting
Firm
We consent to the reference to our firm
under the caption “Experts” in the Registration Statement (Form F-3) and related Prospectus of Kamada Ltd. for the registration
of its ordinary shares and to the incorporation by reference therein of our reports dated March 15, 2023, with respect to the consolidated
financial statements of Kamada Ltd. and the effectiveness of internal control over financial reporting of Kamada Ltd. included in
its Annual Report (Form 20-F) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.
|
/s/ KOST, FORER, GABBAY & KASIERER |
Tel Aviv, Israel |
KOST, FORER, GABBAY & KASIERER |
September 11, 2023 |
A Member of Ernst & Young Global |
Exhibit 107
Calculation of Filing Fee Tables
FORM F-3
(Form Type)
KAMADA LTD.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward
Securities
| |
Security Type | |
Security Class Title | |
Fee Calculation or Carry Forward Rule | |
Amount Registered | | |
Proposed Maximum Offering Price Per Unit | | |
Maximum Aggregate Offering Price | | |
Fee Rate | | |
Amount of Registration Fee | |
| |
Newly Registered Securities | |
Fees to be Paid | |
Equity | |
Ordinary shares, par value NIS 1.0 per share | |
Rule 457(o) | |
| | (1) (2 ) |
| | (3) | |
$ | | 50,000,000 | |
| | 0.00011020 | |
| | 5,510 |
| |
| |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Carry Forward Securities | |
Carry Forward Securities | |
N/A | |
N/A | |
N/A | |
| N/A | | |
N/A | | | |
| N/A | | |
| N/A | | |
| N/A | |
| |
Total Offering Amounts | | |
| | | |
$ | 50,000,000 | | |
| | | |
$ | 5,510 | |
| |
Total Fees Previously Paid | | |
| | | |
| | | |
| | | |
$ | 0.00 | |
| |
Total Fee Offsets | | |
| | | |
| | | |
| | | |
$ | 0.00 | |
| |
Net Fee Due | | |
| | | |
$ | 50,000,000 | | |
| | | |
$ | 5,510 | |
| (1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended
(the “Securities Act”), this registration statement shall be deemed to cover any additional securities to be offered or issued
from stock splits, stock dividends or similar transactions with respect to the shares being registered. |
| (2) | An indeterminate aggregate number of ordinary shares is being
registered as may from time to time be sold at indeterminate prices, with the maximum aggregate public offering price not to exceed $50,000,000.
Separate consideration may or may not be received for ordinary shares that are issuable on exercise, conversion or exchange of other
ordinary shares. |
| (3) | The proposed maximum offering price per unit will be
determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder
and is not specified pursuant to General Instruction II.D. of Form F-3 under the Securities Act. |
Kamada (NASDAQ:KMDA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Kamada (NASDAQ:KMDA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024